- Home
- SGHT vs PLX Comparison
SGHT vs PLX Comparison
Compare SGHT & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGHT
- PLX
- Stock Information
- Founded
- SGHT 2011
- PLX 1993
- Country
- SGHT United States
- PLX United States
- Employees
- SGHT N/A
- PLX N/A
- Industry
- SGHT Medical Specialities
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SGHT Health Care
- PLX Health Care
- Exchange
- SGHT Nasdaq
- PLX Nasdaq
- Market Cap
- SGHT 193.2M
- PLX 204.9M
- IPO Year
- SGHT 2021
- PLX 1998
- Fundamental
- Price
- SGHT $5.24
- PLX $2.36
- Analyst Decision
- SGHT Buy
- PLX Strong Buy
- Analyst Count
- SGHT 8
- PLX 1
- Target Price
- SGHT $4.50
- PLX $15.00
- AVG Volume (30 Days)
- SGHT 221.6K
- PLX 1.1M
- Earning Date
- SGHT 11-06-2025
- PLX 11-13-2025
- Dividend Yield
- SGHT N/A
- PLX N/A
- EPS Growth
- SGHT N/A
- PLX N/A
- EPS
- SGHT N/A
- PLX 0.08
- Revenue
- SGHT $76,303,000.00
- PLX $61,948,000.00
- Revenue This Year
- SGHT N/A
- PLX $14.53
- Revenue Next Year
- SGHT $12.04
- PLX $75.77
- P/E Ratio
- SGHT N/A
- PLX $30.48
- Revenue Growth
- SGHT N/A
- PLX 62.79
- 52 Week Low
- SGHT $2.03
- PLX $1.02
- 52 Week High
- SGHT $5.52
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- SGHT 76.45
- PLX 55.84
- Support Level
- SGHT $3.22
- PLX $1.60
- Resistance Level
- SGHT $5.32
- PLX $2.55
- Average True Range (ATR)
- SGHT 0.31
- PLX 0.16
- MACD
- SGHT 0.22
- PLX -0.03
- Stochastic Oscillator
- SGHT 93.93
- PLX 72.51
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.